Insights

Life sciences industry’s response to COVID-19 disruptions has evolved over the course of the year. The SARS-CoV-2 virus, first emerged as an unknown pneumonia-like disease in December 2019, and ultimately gained the status of ...

Formulating an ethical and potent vaccine against novel pathogens typically takes years. Globally, scientists, pharmaceutical firms, and regulators are arduously working to answer the most palpable question – a COVID-19 vaccine. W...

The rapid spread of the COVID-19 pandemic has redefined the global landscape, forcing governments and organizations to re-evaluate their legacy approach to business. In this report, we look at how the pandemic is affecting the adopt...

Artificial Intelligence (AI) is bringing about a paradigm shift in healthcare, powered by the increasing availability of medical data and the rapid progress of analytical techniques. From catalyzing drug discovery to using data-driv...

The global biosimilar market is expected to reach USD 36 billion by 2022. However, only some countries are favorable for biosimilars due to reasons ranging from poor accessibility to unconducive regulatory environments. This infogra...